Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jurij Hanzel

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Scandinavian Journal of Gastroenterology|November 14, 2023
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategiesSuzanne I Anjie, Jurij Hanzel, Krisztina B Gecse, et al.
Drugs|January 5, 2021
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel DiseaseJurij Hanzel, Christopher Ma, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics|September 24, 2021
Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitisJurij Hanzel, Laura H Bukkems, Krisztina B Gecse, et al.
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Inflammatory Bowel Diseases|May 20, 2021
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort StudyJurij Hanzel, Jeroen M Jansen, Rinze W F Ter Steege, et al.
Journal of Crohn'S & Colitis|January 2, 2025
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJoep van Oostrom, Jurij Hanzel, Bram Verstockt, et al.
Journal of Crohn'S & Colitis|December 21, 2023
Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic ReviewSudheer K Vuyyuru, Virginia Solitano, Siddharth Singh, et al.
Clinical and Translational Gastroenterology|August 14, 2023
A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-AnalysisJurij Hanzel, Virginia Solitano, Lily Zou, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Scandinavian Journal of Gastroenterology|November 14, 2023
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategiesSuzanne I Anjie, Jurij Hanzel, Krisztina B Gecse, et al.
Drugs|January 5, 2021
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel DiseaseJurij Hanzel, Christopher Ma, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics|September 24, 2021
Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitisJurij Hanzel, Laura H Bukkems, Krisztina B Gecse, et al.
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Inflammatory Bowel Diseases|May 20, 2021
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort StudyJurij Hanzel, Jeroen M Jansen, Rinze W F Ter Steege, et al.
Journal of Crohn'S & Colitis|January 2, 2025
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJoep van Oostrom, Jurij Hanzel, Bram Verstockt, et al.
Journal of Crohn'S & Colitis|December 21, 2023
Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic ReviewSudheer K Vuyyuru, Virginia Solitano, Siddharth Singh, et al.
Clinical and Translational Gastroenterology|August 14, 2023
A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-AnalysisJurij Hanzel, Virginia Solitano, Lily Zou, et al.
Pageof 5